

# Detection of 1,2-hydride shifts in the formation of euph-7-ene by the squalene–tetrahymanol cyclase of *Tetrahymena pyriformis*

José-Luis Giner,<sup>†a</sup> Stefano Rocchetti,<sup>a</sup> Serge Neunlist,<sup>b</sup> Michel Rohmer<sup>c</sup> and Duilio Arigoni<sup>\*a</sup>

Received (in Cambridge, UK) 29th March 2005, Accepted 18th April 2005

First published as an Advance Article on the web 13th May 2005

DOI: 10.1039/b504300j


Incubation of samples of 2,3-dihydrosqualene, specifically labeled with deuterium at either carbon position 7 or 11, with an enzyme extract from *Tetrahymena pyriformis*, containing a squalene–tetrahymanol cyclase, provided specimens of euph-7-enes displaying deuterium patterns consistent with the biosynthetic operation of two consecutive 1,2-hydride shifts.

A cyclase from the ciliate protozoan *Tetrahymena pyriformis* is capable of cyclizing squalene in its all-chair conformation, **1**, to the pentacyclic triterpene alcohol tetrahymanol, **2**. According to the experimental evidence, the cyclization is initiated by protonation of a terminal double bond and the process terminated by the quenching of the resulting pentacyclic carbocation with water (Scheme 1a).<sup>1</sup> Later, Abe and Rohmer reported that the same


cyclase can convert 2,3-dihydrosqualene, **3**, into euph-7-ene, **5** (Scheme 1b).<sup>2,3</sup> This unexpected result requires the formation of an intermediate tetracyclic carbocation, **4**, which in the original work was considered to subsequently undergo transformation into the final product *via* a sequence of two 1,2-hydride shifts and two 1,2-methyl migrations, followed by removal of the axial 7 $\alpha$ -proton (Scheme 1b, **4**  $\rightarrow$  **5**).<sup>2</sup>

A similar set of hydride and methyl migrations had previously been demonstrated in the biosynthesis of lanosterol, **6**, from 2,3-oxidosqualene (Scheme 2a).<sup>4</sup> Moreover, the first tetracyclic, ionic intermediate in this process, **B**, has been shown to have the relative and absolute configuration imposed by the chair conformation, **A**, of the corresponding segment of the acyclic precursor. The (20*R*)-configuration of the resulting lanosterol has been interpreted as the outcome of a least-motion pathway for the first hydride shift.<sup>5</sup>

Compounds **5** and **6** display antipodal configurations at the three chiral centers C-13, -14 and -17, of their D-rings, while sharing an identical (*R*)-configuration at C-20. For this reason, a mirror image version of the scheme demonstrated for **6** (Scheme 2a) cannot be applied to the formation of **5**, since it



**Scheme 1** Cyclization reactions of *Tetrahymena pyriformis*: (a) Formation of tetrahymanol (**2**) from squalene (**1**). (b) Formation of euph-7-ene (**5**) from dihydrosqualene (**3**).



**Scheme 2** (a) The stereochemical pathway of the reactions leading to the (20*R*)-configuration of lanosterol (**6**). (b) The hypothetical pathway leading to the (20*R*)-configuration of euph-7-ene (**5**).


<sup>†</sup> Current address: Department of Chemistry, State University of New York - ESF, Syracuse, NY 13210, USA. E-mail: jlginer@syr.edu, Fax: 315 470 6856, Tel: 315 470 6895.

\*arigoni@org.chem.ethz.ch

fails to predict its (20*R*)-stereochemistry. Accordingly, this “anomalous” C-20 configuration cannot be interpreted as the result of a least-motion pathway, and other factors must be at work in the specific generation of this chiral center. Nevertheless, an antipodal chair conformation, **C**, for the segment of **3** cyclizing to ring **D** on the way to **5** (Scheme 2b) seems to be a reasonable assumption, since it corresponds to the conformation required for the production of tetrahymanol in a normal cyclization process. Within this assumption, the operation of the 1,3-hydride shift indicated for the resulting tetracyclic ionic intermediate **D** would provide a simple way of explaining the (20*R*)-configuration of the final product. There is a strong precedence for similar 1,3-hydride shifts in sesquiterpene biosynthesis,<sup>6</sup> and the hydrogen bound to C-13 appears to be well positioned for such a process.


To test this hypothesis, we have now synthesized two specimens of dihydrosqualene, **3a** and **3b**, labeled specifically with deuterium at C-7 or C-11, and submitted them to the action of the *Tetrahymena* cyclase. A mixture of the unlabeled aldehydes, corresponding to **7** and **8**, is easily available from **1** using known methods.<sup>7</sup> A mixture of the labeled compounds, each containing 0.85 D, was prepared from **1** by reduction with LiAlD<sub>4</sub> followed by oxidation with PCC. As indicated in Scheme 3, this preparation was converted into a mixture of the *E*-esters **9** and **10**, which were easily separated by argentic silica gel chromatography. The ester **9** was transformed in four steps into the desired **3a**. The second labeled compound, **3b**, was obtained from **10** in eight steps including, *inter alia*, reaction of the appropriate allylic bromide with “cyanomethylcopper”<sup>8</sup> to give **11**, and a copper-catalyzed reaction of a Grignard reagent with the allylic acetate derived from **12**.<sup>9</sup>

The enzymatic cyclizations of 40 mg samples of **3a** and **3b** were carried out as previously described.<sup>3</sup> In each case, the desired product was obtained in *ca.* 40% yield and subjected to NMR and MS analysis. The product from the 7-D compound, **3a**, displayed a singlet at 0.82 ppm in its <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>) instead of the doublet normally found for the C-21 methyl group (0.83 ppm, *J* = 6.6 Hz). The MS of the compound showed characteristic peaks at *m/z* 413 and 299, corresponding to the molecular ion



**Scheme 3** Far = farnesyl. Reagents, conditions and yields as follows: i. Ph<sub>3</sub>P=C(CH<sub>3</sub>)COOEt (1.2 equiv.), benzene, rt, 87%; ii. LiAl(OEt)H<sub>3</sub> (4 equiv.), Et<sub>2</sub>O, 0 °C, 93%; iii. PBr<sub>3</sub> (1 equiv.), Et<sub>2</sub>O, 0 °C, 73%; iv. (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>SO<sub>2</sub>Ph (1.8 equiv.), *n*-BuLi (1.8 equiv.), THF-HMPT 10 : 1, -78 °C to rt, 89%; v. 6% Na-Hg (6 equiv.), Na<sub>2</sub>HPO<sub>4</sub> (4 equiv.), MeOH, 0 °C, 73%; vi. CH<sub>3</sub>CN (10 equiv.), *n*-BuLi (10 equiv.), CuI (1 equiv.), THF, -25 °C to rt, 83%; vii. DIBAL (1.1 equiv.), PhCH<sub>3</sub>, 0 °C to rt, then 10% HOAc-H<sub>2</sub>O, 97%; viii. Ac<sub>2</sub>O-pyridine 1 : 1 (large excess), rt, 100%; ix. (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>CH<sub>2</sub>MgBr (4 equiv.), Li<sub>2</sub>CuCl<sub>4</sub> (0.04 equiv.), THF, -78 °C to rt, (29–60% recovered as **12**).

(C<sub>30</sub>H<sub>51</sub>D<sup>+</sup>) and a fragment arising from it by loss of a deuterated side chain (M<sup>+</sup>-C<sub>8</sub>H<sub>16</sub>D) respectively. These results clearly demonstrate that the product of the enzymatic cyclization of **3a** bears its deuterium label at C-20 (**5a**). In keeping with this finding, the product from the 11-D compound, **3b**, shows the normal pattern of signals in the methyl region of its <sup>1</sup>H NMR spectrum and a peak at *m/z* 300 in the MS, consistent with the elimination of an unlabeled side chain from the molecular ion (M<sup>+</sup>-C<sub>8</sub>H<sub>17</sub>). This is consistent with the presence of a deuterium label at C-17 (**5b**). The outcomes of the two complementary experiments rule out the operation of the putative 1,3-hydride shift and demonstrate that the rearrangement process leading to **5** is initiated, as in the case of **6**, by a 1,2-hydride shift from C-17 to C-20. Proof of the stereochemistry of the dammaranyl cation involved in this process will be presented in a separate communication.



In addition, two by-products, **13** and **14**, were produced in both enzyme experiments in their deuterated forms, each as *ca.* 5% of the total product. The two isomers could be separated from one another by argentic silica gel chromatography, and displayed molecular ions at *m/z* = 413 (C<sub>30</sub>H<sub>49</sub>D). Both compounds were shown to be bicyclic triterpene-trienes on the basis of their <sup>1</sup>H NMR spectra. <sup>1</sup>H NMR spectra (CDCl<sub>3</sub>) of **13a** and **13b** showed seven methyl groups: two allylic methyl signals overlapping at 1.59 ppm, three methyl singlets at 0.87, 0.80 and 0.66 ppm, and two overlapping methyl doublets at 0.86 ppm (*J* = 6.6 Hz). Both **13a** and **13b** showed two olefinic singlets at 4.82 and 4.54 ppm, indicative of an *exo*-methylene group, as well as a signal at 5.11 ppm (triplet, *J* = 6 Hz). The NMR data for **14a** and **14b** were similar, but eight methyl groups were detected: three allylic methyl signals at 1.71, 1.61, and 1.58 ppm, three methyl singlets at 0.87, 0.85, and 0.74 ppm, and two overlapping methyl doublets at 0.86 ppm (*J* = 6.6 Hz). Both **14a** and **14b** exhibited an olefinic signal at 5.38 (multiplet). In addition, **14a** showed a signal at 5.14 (triplet, *J* = 6 Hz), while **14b** had a signal at 5.11 (triplet, *J* = 6 Hz). The new structures assigned to the type **13** and **14** compounds are closely related to those of  $\alpha$ - and  $\gamma$ -polypodatetraene, two natural products from ferns, from which they differ only by lack of the isopropylidene double bonds.<sup>10</sup> Similar bicyclic compounds have previously been isolated from the incubation products of long chain polyprenyl ethers with the same cyclase.<sup>11</sup> The formation of these products is best visualized as being an interception of the bicyclic, ionic intermediates by the same base which mediates in the position 7 deprotonation during formation of **5**. In contrast, no corresponding bicyclic products can be detected from the incubation of natural substrate **1** with the cyclase. It seems noteworthy that a relatively minor change, such as the removal of the double bond at a remote center, is sufficient to influence the sequence of events which follow the second cyclization step.‡

José-Luis Giner,<sup>†a</sup> Stefano Rocchetti,<sup>a</sup> Serge Neunlist,<sup>b</sup> Michel Rohmer<sup>c</sup>  
and Duilio Arigoni<sup>\*a</sup>

<sup>a</sup>Laboratorium für Organische Chemie, ETH-Hönggerberg HCI H307,  
CH-8093, Zürich, Switzerland. E-mail: arigoni@org.chem.ethz.ch;  
Fax: 41-44-6321154; Tel: 41-44-6322891

<sup>b</sup>Ecole National Supérieure de Chimie de Mulhouse, 3 rue A. Werner,  
68093, Mulhouse Cedex, France. E-mail: S.Neunlist@uha.fr;  
Fax: 33 (0)3 89 33 68 60; Tel: 33 (0)3 89 33 68 76

<sup>c</sup>Université Louis Pasteur, Institut Le Bel, 4 rue Blaise Pascal, 67070,  
Strasbourg Cédex, France. E-mail: mirohmer@chimie.u-strasbg.fr;  
Fax: 33 (0)3 90 24 13 45; Tel: 33 (0)3 90 24 13 46

## Notes and references

† An analogous situation has been detected in the case of the related squalene-hopene cyclase of *Alicyclobacillus acidocaldarius*. While polydatetraenes are not generated from squalene by the wild type cyclase, their production has been detected with mutated forms of the enzyme.<sup>12</sup>

- 1 E. Caspi, *Acc. Chem. Res.*, 1980, **13**, 97–104 and references cited therein.
- 2 I. Abe and M. Rohmer, *J. Chem. Soc., Chem. Commun.*, 1991, 902–903.
- 3 I. Abe and M. Rohmer, *J. Chem. Soc., Perkin Trans. 1*, 1994, 783–791.

- 4 D. H. R. Barton, G. Mellows, D. A. Widdowson and J. J. Wright, *J. Chem. Soc. C*, 1971, 1142–1148 and references cited therein.
- 5 E. J. Corey and S. C. Virgil, *J. Am. Chem. Soc.*, 1991, **113**, 4025–4026.
- 6 (a) D. Arigoni, *Pure Appl. Chem.*, 1975, **41**, 219–245; (b) R. Masciardi, W. Angst and D. Arigoni, *J. Chem. Soc., Chem. Commun.*, 1985, 1573–1574; (c) D. Cane, Biosynthesis of sesquiterpenes, in *Biosynthesis of Isoprenoid Compounds*, ed. J. W. Porter and L. Spurgeon, John Wiley and Sons, New York, 1981, vol. 1, ch. 6, p. 339 ff.; (d) D. E. Cane and M. Tandon, *J. Am. Chem. Soc.*, 1995, **117**, 5602–5603; (e) K. Nabeta, K. Kigure, M. Fujita, T. Nagoya, T. Ishikawa, H. Okuyama and T. Takasawa, *J. Chem. Soc., Perkin Trans. 1*, 1995, 1935–1939.
- 7 M. Ceruti, F. Viola, F. Dosio, L. Cattel, P. Bouvier-Navé and P. Ugliengo, *J. Chem. Soc., Perkin Trans. 1*, 1988, 461–469.
- 8 E. J. Corey and I. Kuwajima, *Tetrahedron Lett.*, 1972, **13**, 487–489.
- 9 G. Fouquet and M. Schlosser, *Angew. Chem.*, 1974, **86**, 50–51.
- 10 K. Shiojima, Y. Arai, K. Masuda, T. Kamada and H. Ageta, *Tetrahedron Lett.*, 1983, **24**, 5733–5736.
- 11 J.-M. Renoux and M. Rohmer, *Eur. J. Biochem.*, 1986, **155**, 125–132.
- 12 (a) C. Pale-Grosdemange, T. Merkofer, M. Rohmer and K. Poralla, *Tetrahedron Lett.*, 1999, **40**, 6009–6012; (b) T. Hoshino and T. Sato, *Chem. Commun.*, 1999, 2005–2006.